ライフサイエンスコーパス: respiratory distress syndrome

1 o-venous) for medical indications (78% acute respiratory distress syndrome).

2 Consecutive subjects with acute respiratory distress syndrome.

3 ciated with a lower incidence of early acute respiratory distress syndrome.

4 by increasing their susceptibility to acute respiratory distress syndrome.

5 e option for future clinical trials in acute respiratory distress syndrome.

6 for treatment of pathological states such as respiratory distress syndrome.

7 pulmonary vascular mechanics in early acute respiratory distress syndrome.

8 4 months thereafter, until 5 years postacute respiratory distress syndrome.

9 3, 6, 12, 24, 36, and 48 months after acute respiratory distress syndrome.

10 the severity of rodent E. coli-induced acute respiratory distress syndrome.

11 rotective ventilation in patients with acute respiratory distress syndrome.

12 ated with lower mortality in pediatric acute respiratory distress syndrome.

13 in predicting outcome in patients with acute respiratory distress syndrome.

14 d-expiratory pressures in experimental acute respiratory distress syndrome.

15 ean Consensus Conference definition of acute respiratory distress syndrome.

16 delivery of exogenous surfactant in neonatal respiratory distress syndrome.

17 ilation 11.4% of the time patients had acute respiratory distress syndrome.

18 rotective ventilation in patients with acute respiratory distress syndrome.

19 me ventilation lowers mortality in the acute respiratory distress syndrome.

20 greater than or equal to 2 years after acute respiratory distress syndrome.

21 tilation may depend on the etiology of acute respiratory distress syndrome.

22 ated with lung stress and mortality in acute respiratory distress syndrome.

23 irect lung injury leading to pediatric acute respiratory distress syndrome.

24 ain pathophysiologic mechanisms of the acute respiratory distress syndrome.

25 with low tidal volume ventilation for acute respiratory distress syndrome.

26 ted with lung connective tissue during acute respiratory distress syndrome.

27 h the emergency department at risk for acute respiratory distress syndrome.

28 bo for patients with sepsis-associated acute respiratory distress syndrome.

29 permeability, and organ dysfunction in acute respiratory distress syndrome.

30 tem-modulating agents for treatment of acute respiratory distress syndrome.

31 jor risk factor for the development of acute respiratory distress syndrome.

32 developing age-tailored therapies for acute respiratory distress syndrome.

33 n broncho-alveolar lavage fluid during acute respiratory distress syndrome.

34 al of conservative fluid management in acute respiratory distress syndrome.

35 erimental pulmonary and extrapulmonary acute respiratory distress syndrome.

36 hronic inflammatory diseases including acute respiratory distress syndrome.

37 y distress syndrome and extrapulmonary acute respiratory distress syndrome.

38 ctant administration in premature lambs with respiratory distress syndrome.

39 AERD), inflammatory bowel disease, and acute respiratory distress syndrome.

40 hanical ventilation and development of acute respiratory distress syndrome.

41 ds and beta agonists for prevention of acute respiratory distress syndrome.

42 d during mechanical ventilation in the acute respiratory distress syndrome.

43 T cell therapy; five met criteria for acute respiratory distress syndrome.

44 rs old, with moderate/severe pediatric acute respiratory distress syndrome.

45 lled in previously completed trials of acute respiratory distress syndrome.

46 associated with mortality in pediatric acute respiratory distress syndrome.

47 d 778 patients with moderate to severe acute respiratory distress syndrome.

48 IO2 ratio, gender, and the etiology of acute respiratory distress syndrome.

49 easured circulating interleukin-17A in acute respiratory distress syndrome 1 and acute respiratory di

50 In both acute respiratory distress syndrome 1 and acute respiratory di

51 In acute respiratory distress syndrome 1, we used paired serum an

52 rainage (1.7% vs 9.9%, P = 0.006), and acute respiratory distress syndrome (1.7% vs 9.9%, P = 0.006)

53 Of 457 patients with acute respiratory distress syndrome, 106 (23%) were not intuba

54 te respiratory distress syndrome 1 and acute respiratory distress syndrome 2, elevated interleukin-17

55 ry distress syndrome onset, whereas in acute respiratory distress syndrome 2, we used plasma obtained

56 te respiratory distress syndrome 1 and acute respiratory distress syndrome 2.

57 atients in the placebo group developed acute respiratory distress syndrome (7 vs 0) and required mech

58 Acute respiratory distress syndrome adjudication was performed

59 a (adjusted HR, 2.10; 95% CI, 1.90-2.33) and respiratory distress syndrome (adjusted HR, 2.43; 2.21-2

60 In preterm lambs with severe respiratory distress syndrome, aerosol surfactant admini

61 s ratio, 2.43; 95% CI, 1.68-3.49), and acute respiratory distress syndrome after accounting for the c

62 had a 73% increased risk of developing acute respiratory distress syndrome after controlling for age,

63 to fibrocytes; 2) the influence of the acute respiratory distress syndrome alveolar environment on fi

64 births and could be a risk factor to develop respiratory distress syndrome among preterm infants.

65 469 patients (18 tuberculosis-related acute respiratory distress syndrome and 451 acute respiratory

66 re categorized as tuberculosis-related acute respiratory distress syndrome and acute respiratory dist

67 2 alveolar epithelial cells in neonates with respiratory distress syndrome and BPD.

68 venues for therapeutic manipulation in acute respiratory distress syndrome and could have implication

69 proved lung function in both pulmonary acute respiratory distress syndrome and extrapulmonary acute r

70 hosphoinositide 3-kinase inhibition in acute respiratory distress syndrome and highlight the importan

71 etectable in over 90% of patients with acute respiratory distress syndrome and is associated with deg

72 result in serious outcomes, including acute respiratory distress syndrome and multi-organ failure in

73 veolar lavage fluid from patients with acute respiratory distress syndrome and multiple models of lun

74 ical trials of promising therapies for acute respiratory distress syndrome and reduce the number of l

75 wenty-five patients (19 mild-to-severe acute respiratory distress syndrome and six matched ventilated

76 mized clinical trial of hypothermia in acute respiratory distress syndrome and the feasibility of stu

77 commonly for diagnosis of lung injury (acute respiratory distress syndrome and transfusion-related ac

78 auma, infection, sepsis, endotoxin and acute respiratory distress syndrome) and matched mouse models,

79 led, including 47 meeting criteria for acute respiratory distress syndrome, and 32 failed noninvasive

80 patients with sepsis and septic shock, acute respiratory distress syndrome, and major trauma have bee

81 ower incidence of acute kidney injury, acute respiratory distress syndrome, and need for vasopressors

82 scular resistance predict mortality in acute respiratory distress syndrome, and pulmonary arterial co

83 ion >/=24 h, stillbirth, or neonatal death); respiratory distress syndrome; any mechanical ventilatio

84 hock, multiple organ failure including acute respiratory distress syndrome (ARDS) and acute renal fai

85 Although acute respiratory distress syndrome (ARDS) and progressive pul

86 Sepsis and the acute respiratory distress syndrome (ARDS) are major causes of

87 ed to help drive early pathogenesis in acute respiratory distress syndrome (ARDS) by enhancing neutro

88 3 was also associated with the risk of acute respiratory distress syndrome (ARDS) in an intensive car

89 Acute respiratory distress syndrome (ARDS) is associated with

90 RATIONALE: Acute respiratory distress syndrome (ARDS) is caused by widesp

91 Acute respiratory distress syndrome (ARDS) is characterized by

92 Acute respiratory distress syndrome (ARDS) is undefined in neo

93 lation (MV) remains the cornerstone of acute respiratory distress syndrome (ARDS) management.

94 EP) is unknown in patients with severe acute respiratory distress syndrome (ARDS) on extracorporeal m

95 ent data meta-analysis was to identify acute respiratory distress syndrome (ARDS) patient subgroups w

96 on clinical outcomes in patients with acute respiratory distress syndrome (ARDS) remain uncertain.

97 RATIONALE: Acute respiratory distress syndrome (ARDS) remains a major cau

98 Management of acute respiratory distress syndrome (ARDS) remains largely sup

99 Clinical factors alone poorly explain acute respiratory distress syndrome (ARDS) risk and ARDS outco

100 ATIONALE: We previously identified two acute respiratory distress syndrome (ARDS) subphenotypes in tw

101 Clinicians who treat patients with acute respiratory distress syndrome (ARDS) use information and

102 In the 50 years since acute respiratory distress syndrome (ARDS) was first described

103 RATIONALE: Following acute respiratory distress syndrome (ARDS), joblessness is com

104 el virus that emerged in 2012, causing acute respiratory distress syndrome (ARDS), severe pneumonia-l

105 In clinical trials of therapies for acute respiratory distress syndrome (ARDS), the average treatm

106 anding and management of patients with acute respiratory distress syndrome (ARDS), the morbidity and

107 severe pneumonia is the main cause of acute respiratory distress syndrome (ARDS), we aimed to invest

108 iruses (IAV) can cause lung injury and acute respiratory distress syndrome (ARDS), which is character

109 ilation since the first description of acute respiratory distress syndrome (ARDS).

110 cal ventilation in adult patients with acute respiratory distress syndrome (ARDS).

111 on consensus definition of sepsis and acute respiratory distress syndrome (ARDS).

112 dotracheal intubation in patients with acute respiratory distress syndrome (ARDS).

113 ent, and outcomes of patients with the acute respiratory distress syndrome (ARDS).

114 is increasingly used in patients with acute respiratory distress syndrome (ARDS).

115 ffects have never been investigated in acute respiratory distress syndrome (ARDS).

116 th factor (KGF) might be beneficial in acute respiratory distress syndrome (ARDS).

117 n the management of many patients with acute respiratory distress syndrome (ARDS).

118 ome has been as extensively studied as acute respiratory distress syndrome (ARDS).

119 ged as a potential new therapeutic for acute respiratory distress syndrome (ARDS).

120 agement, and outcomes of patients with acute respiratory distress syndrome (ARDS).

121 nniversary of the first description of acute respiratory distress syndrome (ARDS).

122 Acute kidney injury and acute respiratory distress syndrome are both independent risks

123 eting lung injury in patients with the acute respiratory distress syndrome are lacking.

124 glycemia (aRR, 1.53; 95% CI, 1.34-1.75), and respiratory distress syndrome (aRR, 1.48; 95% CI, 1.30-1

125 talized patients at risk of developing acute respiratory distress syndrome at the time of critical ca

126 Patients with acute respiratory distress syndrome at the time of initial con

127 trospective review of 58 patients with acute respiratory distress syndrome based on Berlin criteria a

128 Mechanically ventilated children with acute respiratory distress syndrome (Berlin).

129 xtracorporeal membrane oxygenation for acute respiratory distress syndrome between 2010 and 2015.

130 Acute respiratory distress syndrome blood and alveolar neutrop

131 ion decreased the inhibitory effect of acute respiratory distress syndrome broncho-alveolar lavage fl

132 lenishment of serum amyloid P-depleted acute respiratory distress syndrome broncho-alveolar lavage fl

133 Acute respiratory distress syndrome broncho-alveolar lavage fl

134 serve as rescue therapy in refractory acute respiratory distress syndrome but has not been assessed

135 ggest hypothermia may be beneficial in acute respiratory distress syndrome, but cooling causes shiver

136 In pulmonary acute respiratory distress syndrome, but not in extrapulmonary

137 After induction of acute respiratory distress syndrome by hydrochloric acid insti

138 eta agonists may reduce progression to acute respiratory distress syndrome by reducing lung inflammat

139 vacuolating toxin called community-acquired respiratory distress syndrome (CARDS) toxin is capable o

140 Only 7 of 133 acute respiratory distress syndrome cases met criteria for eng

141 In preterm lambs with respiratory distress syndrome, cerebral blood flow, regi

142 a major cause of acute lung injury and acute respiratory distress syndrome, characterized by alveolar

143 The diseases reviewed include acute respiratory distress syndrome, chronic obstructive pulmo

144 t a promising therapeutic strategy for acute respiratory distress syndrome, clinical translation face

145 In acute respiratory distress syndrome, conservative fluid manage

146 Acute respiratory distress syndrome continues to represent an

147 enation index over the first 7 days of acute respiratory distress syndrome could discriminate between

148 sence of fibrocytes in the lung during acute respiratory distress syndrome could result in a balance

149 Acute respiratory distress syndrome criteria were recorded.

150 bated at the time of meeting all other acute respiratory distress syndrome criteria.

151 nflammatory cytokines were measured on acute respiratory distress syndrome day 1 and correlated with

152 mechanically ventilated patients with acute respiratory distress syndrome demonstrates that implemen

153 Acute respiratory distress syndrome developed in 75 patients (

154 Median time to acute respiratory distress syndrome development was 55.4 days

155 Patients were screened for acute respiratory distress syndrome development within 1 year

156 epsis that correlate with survival and acute respiratory distress syndrome development, thus suggesti

157 linical indices were not predictive of acute respiratory distress syndrome development.

158 and plateau pressure at 24 hours after acute respiratory distress syndrome diagnosis was associated w

159 g pressure evaluated at 24 hours after acute respiratory distress syndrome diagnosis while ventilated

160 drome due to tuberculosis behaves like acute respiratory distress syndrome due to other causes and do

161 Acute respiratory distress syndrome due to tuberculosis behave

162 During the acute respiratory distress syndrome, epithelial cells, primari

163 volume-controlled ventilation in both acute respiratory distress syndrome etiologies.

164 pared with nonventilated regardless of acute respiratory distress syndrome etiology.

165 Tuberculosis is an uncommon cause of acute respiratory distress syndrome even in high tuberculosis

166 oxygenation therapy in case of severe acute respiratory distress syndrome failing conventional measu

167 Most cases of acute respiratory distress syndrome following hematopoietic st

168 venous infusion early in the course of acute respiratory distress syndrome for patients with a PaO2/F

169 al criteria for sepsis (six trials) or acute respiratory distress syndrome (four trials), use of inva

170 en with indirect lung injury pediatric acute respiratory distress syndrome have a lower risk of morta

171 h incidence and mortality of pediatric acute respiratory distress syndrome have not changed over the

172 .73; 95% CI, 2.39-5.82; p < 0.001) and acute respiratory distress syndrome (hazard ratio, 2.16; 95% C

173 , reason for connection different from acute respiratory distress syndrome, higher simplified acute p

174 adverse prognosis in patients with the acute respiratory distress syndrome; however, the prognostic i

175 piratory insufficiency in 141 (11.6%), acute respiratory distress syndrome in 84 (6.9%), pulmonary in

176 Our understanding of the acute respiratory distress syndrome in children is limited, an

177 A significant increase of respiratory distress syndrome in colonized group, even a

178 steroid receipt and the development of acute respiratory distress syndrome in critically ill patients

179 to defective T and B cell function and acute respiratory distress syndrome in early childhood.

180 erimental animals and diseases such as acute respiratory distress syndrome in humans.

181 te kidney injury increases the risk of acute respiratory distress syndrome in mechanically ventilated

182 sociated with adverse prognosis in the acute respiratory distress syndrome in small and single-center

183 e associated with a lower incidence of acute respiratory distress syndrome in the 96 hours after ICU

184 xtracorporeal membrane oxygenation for acute respiratory distress syndrome in this group.

185 understand the risk factors underlying acute respiratory distress syndrome in this population, thereb

186 The incidence and outcomes of acute respiratory distress syndrome in this setting are poorly

187 Forty-two patients with acute respiratory distress syndrome in whom airflow, airway pr

188 gnificant gaps in our understanding of acute respiratory distress syndrome, in part due to the lack o

189 Acute respiratory distress syndrome is a frequent complication

190 The acute respiratory distress syndrome is a frequent condition fo

191 Acute respiratory distress syndrome is a multifactorial lung i

192 Whether tuberculosis-related acute respiratory distress syndrome is associated with worse o

193 RATIONALE: Acute respiratory distress syndrome is characterized by alveol

194 ide/formoterol in patients at risk for acute respiratory distress syndrome is feasible and improved o

195 ct of pulmonary arterial compliance in acute respiratory distress syndrome is not established.

196 Acute respiratory distress syndrome led to pulmonary vascular

197 r of significant human pathologies including respiratory distress syndrome, lung adenocarcinoma, and

198 In pediatric acute respiratory distress syndrome, lung injury is mediated b

199 In a reciprocal multivariate analysis, acute respiratory distress syndrome (n = 299; 36%) demonstrate

200 dministered intratracheally (pulmonary acute respiratory distress syndrome, n = 12) or intraperitonea

201 ) or intraperitoneally (extrapulmonary acute respiratory distress syndrome, n = 12).

202 In this experimental model, Acute Respiratory Distress Syndrome Network and open lung appr

203 nary vascular mechanics was similar in Acute Respiratory Distress Syndrome Network and open lung appr

204 Forty-one Acute Respiratory Distress Syndrome Network hospitals across t

205 Forty-two ICUs across 17 Acute Respiratory Distress Syndrome Network hospitals.

206 o 4 hours ventilation according to the Acute Respiratory Distress Syndrome Network protocol or to an

207 ventilator-free day outcomes in three Acute Respiratory Distress Syndrome Network studies used for t

208 Open lung approach as compared to Acute Respiratory Distress Syndrome Network was associated wit

209 r levels in 194 patients, including 38 acute respiratory distress syndrome nonsurvivors.

210 e associated with a lower incidence of acute respiratory distress syndrome (odds ratio for 30 mg of p

211 icantly associated with development of acute respiratory distress syndrome (odds ratio, 1.31; 95% CI,

212 was associated with the development of acute respiratory distress syndrome (odds ratio, 4.17; 95% CI,

213 .041), the most frequent of which were acute respiratory distress syndrome (one [2%] vs two [4%] pati

214 In extrapulmonary acute respiratory distress syndrome, only volume-controlled ve

215 Cdyn, and PaO2/FIO2 were collected at acute respiratory distress syndrome onset and at 24 hours in 3

216 dal volume ventilation within 1 day of acute respiratory distress syndrome onset for greater than or

217 volume during the first 72 hours after acute respiratory distress syndrome onset was never less than

218 At acute respiratory distress syndrome onset, neither mechanical

219 id samples obtained within 48 hours of acute respiratory distress syndrome onset, whereas in acute re

220 dal volume ventilation within 1 day of acute respiratory distress syndrome onset.

221 f tumorigenicity-2) within 24 hours of acute respiratory distress syndrome onset.

222 reated with high-flow nasal cannula at acute respiratory distress syndrome onset.

223 annula and those who were intubated at acute respiratory distress syndrome onset.

224 zed ventilator settings 24 hours after acute respiratory distress syndrome onset.

225 .21-1.42) and the composite outcome of acute respiratory distress syndrome or death (odds ratio, 1.26

226 % CI, 2.26-7.72), composite outcome of acute respiratory distress syndrome or death (odds ratio, 2.43

227 cute respiratory distress syndrome and acute respiratory distress syndrome-others and were managed wi

228 respiratory distress syndrome and 451 acute respiratory distress syndrome-others) with acute respira

229 acute respiratory distress syndrome vs acute respiratory distress syndrome-others; 27.7% vs 28.2%; p

230 ty troponin I (Abbott ARCHITECT), with acute respiratory distress syndrome outcomes, we measured high

231 analysis of all subjects admitted with acute respiratory distress syndrome over the last 16 years.

232 patients with early moderate to severe acute respiratory distress syndrome (PaO2/FiO2 < 200 and withi

233 PaO2/FIO2 </= 300) and moderate-severe acute respiratory distress syndrome (PaO2/FIO2 </= 150).

234 hods better identified moderate-severe acute respiratory distress syndrome (PaO2/FIO2 </= 150); nonli

235 urve for patients meeting criteria for acute respiratory distress syndrome (PaO2/FIO2 </= 300) and mo

236 respiratory distress syndrome than non-acute respiratory distress syndrome patients (48% vs 18%; p <

237 edside to predict the risk of death of acute respiratory distress syndrome patients 24 hours after di

238 r model using individual data from 478 acute respiratory distress syndrome patients and assessed its

239 hdrawal than moderate/severe pediatric acute respiratory distress syndrome patients managed without e

240 ndrome and the feasibility of studying acute respiratory distress syndrome patients receiving neuromu

241 were higher in both groups of matched acute respiratory distress syndrome patients than in both cont

242 does not cause hypothermia but allowed acute respiratory distress syndrome patients to be effectively

243 wing: 1) the ability of monocytes from acute respiratory distress syndrome patients to differentiate

244 omarkers of inflammation and injury to acute respiratory distress syndrome patients undergoing direct

245 One thousand fifty-seven acute respiratory distress syndrome patients were included.

246 eated with high-flow nasal cannula and acute respiratory distress syndrome patients who were directly

247 Nine hundred thirty-four ventilated acute respiratory distress syndrome patients with a central ve

248 uid management decreases mortality for acute respiratory distress syndrome patients with a low initia

249 pective hypothermia treatment in eight acute respiratory distress syndrome patients with PaO2/FIO2 le

250 Obesity has a complex impact on acute respiratory distress syndrome patients, being associated

251 licability in a separate cohort of 300 acute respiratory distress syndrome patients.

252 nnula patients should be considered as acute respiratory distress syndrome patients.

253 for various pulmonary diseases such as acute respiratory distress syndrome, pneumonia, cystic fibrosi

254 monary embolism, deep vein thrombosis, acute respiratory distress syndrome, pneumonia, decubitus ulce

255 In pediatric acute respiratory distress syndrome, pro- and anti-inflammator

256 However, its role as primary therapy for respiratory distress syndrome (RDS) of prematurity needs

257 for high altitude pulmonary edema (HAPE) and respiratory distress syndrome (RDS) using the software R

258 trial of hypothermia in patients with acute respiratory distress syndrome receiving treatment with n

259 ssessed the incidence and mortality of acute respiratory distress syndrome reported in children in st

260 .5), asphyxia (RR = 8.5, 99% CI: 5.7, 11.3), respiratory distress syndrome (RR = 6.5, 99% CI: 5.9, 7.

261 with worse outcomes when compared with acute respiratory distress syndrome secondary to other causes

262 ally ventilated burn patients, whereas acute respiratory distress syndrome similarly demonstrates a s

263 ilure Assessment, PaO2/FIO2, origin of acute respiratory distress syndrome, steroids, renal failure a

264 A derivation cohort from three acute respiratory distress syndrome studies was used to estima

265 Then, for each individual acute respiratory distress syndrome study, the threshold 7-day

266 onary arterial compliance increased in acute respiratory distress syndrome survivors and remained unc

267 l discharge, greater than one third of acute respiratory distress syndrome survivors had muscle weakn

268 Given high co-occurrence, acute respiratory distress syndrome survivors should be simult

269 ric symptoms occurred in two thirds of acute respiratory distress syndrome survivors with frequent co

270 In a multisite cohort of long-term acute respiratory distress syndrome survivors, better annual p

271 ventricular load improve over time in acute respiratory distress syndrome survivors.

272 evaluating the 4-m gait speed test in acute respiratory distress syndrome survivors.

273 One hundred fifty-six acute respiratory distress syndrome survivors.

274 ultivariable adjustment, age, cause of acute respiratory distress syndrome, temperature, heart rate,

275 as 22% and was significantly higher in acute respiratory distress syndrome than non-acute respiratory

276 ntilation, the mean (SD) percentage of acute respiratory distress syndrome time it was used was 59.1%

277 impact of right ventricular protective acute respiratory distress syndrome treatment on right ventric

278 Acute respiratory distress syndrome trials powered for mortali

279 ensive studies of myocardial injury in acute respiratory distress syndrome using modern high-sensitiv

280 ss syndrome, but not in extrapulmonary acute respiratory distress syndrome, variable ventilation 1) d

281 d mononuclear cells were isolated from acute respiratory distress syndrome, ventilated controls, and

282 n the two groups (tuberculosis-related acute respiratory distress syndrome vs acute respiratory distr

283 and PICU-based incidence of pediatric acute respiratory distress syndrome was 3.5 (95% CI, 2.2-5.7)

284 Acute respiratory distress syndrome was induced by Escherichia

285 Acute respiratory distress syndrome was induced by repeated lu

286 Acute respiratory distress syndrome was induced combining sali

287 Mild acute respiratory distress syndrome was induced in 10 anesthet

288 Acute respiratory distress syndrome was induced in rats by int

289 The main reason for acute respiratory distress syndrome was pneumonia in 81% of pa

290 In lung tissue from patients with acute respiratory distress syndrome, we identified increased e

291 iratory distress syndrome-others) with acute respiratory distress syndrome were admitted.

292 oportion of critically ill adults with acute respiratory distress syndrome were not intubated in thei

293 ts (5%) with moderate/severe pediatric acute respiratory distress syndrome were supported on extracor

294 ix matched ventilated controls without acute respiratory distress syndrome) were enrolled.

295 ere associated with the development of acute respiratory distress syndrome, whereas other traditional

296 gency department patients experiencing acute respiratory distress syndrome while in the emergency dep

297 spective analysis of 363 subjects with acute respiratory distress syndrome who had complete baseline

298 t pneumonia that rapidly progresses to acute respiratory distress syndrome with a fatal outcome remin

299 The unadjusted occurrence rate of acute respiratory distress syndrome within 96 hours of ICU adm

300 After inducing acute respiratory distress syndrome, Z0 and effective arterial